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17 The specific research aims are further detailed below. We are happy to report that we have been able to successfully reach all major goals and complete all milestones, as originally planned.
KEYWORDS:
ovarian cancer, preclinical models, disease pathogenesis, Kras, Pten, cancer vaccines, MUC1, immune checkpoint.
3. ACCOMPLISHMENTS 3.1. Major research goals of the projects Our work was conducted around the following three aims: Aim 1: To investigate the müllerian tract versus the OSE as the potential originating sites for ovarian epithelial tumors in KrasPten mice Aim 2: To profile disease heterogeneity and to identify immune biomarkers of natural and vaccine-induced immune responses in mice with either endometriosis, ovarian cancer or endometriosis progressing to ovarian cancer. Aim 3: To identify human immune biomarkers of endometriosis and cancer and to validate in human specimens the disease biomarkers identified (in aim 2) in mice with endometriosis and ovarian tumors. All aims have been completed and results have been published or are currently under review. Accomplishments under each aim are further detailed below. Using complex genetic models with conditional mutations in Kras, Pten or both we have uncovered the following major findings: 1. Morphopathogenic characteristics of lesions triggered by AdCre injections via intrabursal, intraductal and intrauterine routes are highly heterogeneous and are accompanied by various immune microenvironments at each location. Similarly to the ovarian tumors, tumors triggered in oviducts and endometrium have endometrioid histology ( Fig. 1 ) and express increased levels of human MUC1 antigen, similar to MUC1 levels seen in human tumors (Fig. 2) . Background levels were detected using sera from KrasPten mice with MUC1 negative tumors (i.e. wildtype for MUC1). Vehicle only was also included as an additional negative control. The assay was run in duplicate and values were plotted as means with standard deviations. Lower panel: box and whisker diagrams (min, Q1, median, Q3, max) of readings at 1∶20 dilution. Antibody levels are significantly higher (compared to control readings) in the ovarian and oviduct tumor group (one way ANOVA p<0.05; *two tail t test; p<0.05). 2. Oviducts seem to favor the development of high grade tumors, providing preclinical evidence in support of the postulated role of fallopian tubes as the originating site for high grade human ovarian tumors (Fig. 3) . 3 . Survival for oviduct tumors was significantly lower than for endometrial tumors (p = 0.0015), yet similar to survival for ovarian cancer (Fig. 3 ).
4. An increased Foxp3 + T cell accumulation in the spleen of oviduct tumor-bearing mice and a higher ratio of Treg/CD8 in these mice compared to mice with uterine tumors (Fig. 3C, p<0 .01). No differences were noted between mice with ovarian and oviduct tumors, suggesting that both anatomical locations are similar in inducing an immune suppressive phenotype in the host, despite the high nuclear grade observed only in the latter. Using triple transgenic mice with MUC1 expressing orthotopic ovarian tumors we were able to demonstrate how MUC1 influences biology of ovarian tumors and to explore the in vivo efficacy of MUC1 based vaccine (Budiu et al, Oncogene 2013 PMID: 22964632). Specifically, we showed that the triple Tg mice had an average of 2.6 metastatic sites versus 1.4 in double Tg mice (P = 0.03, Table 1 ), suggesting that the MUC1-expressing tumors migrate and metastasize more widely in the peritoneal cavity, a hypothesis further tested in cell lines (Fig. 4) . (c) Invasion of IG10 and IG10-MUC1 cell lines before and after transient knockdown of human MUC1 and mouse Cdh11 with specific siRNAs. The cells were grown in vitro in the presence of negative control siRNA, MUC1 or Cdh11 specific siRNA, for 48 h and then subjected to invasion assay (described in Materials and methods). Each assay was run in triplicate and results from one of four independent assays are shown. The bars represent the averaged fluorescence readings. *IG10 compared with IG10-MUC1, no treatment (P = 0.0068); **IG10 compared with IG10-MUC1, cells treated with negative control siRNA (P = 0.007); ***IG10 compared with IG10-MUC1, cells treated with four different siRNA specific to human MUC1 (P = 0.00007); ****IG10 compared with IG10-MUC1, cells treated with four different siRNA specific to mouse Cdh11 (P = 0.0034). Student's t-test. (d) Cdh11 expression by qRT-PCR. RNA was extracted from frozen KrasPten (n = 4) and MUC1KrasPten ovarian tumors (n= 4). All results were normalized to a pool of three housekeeping genes (Gusb, Hsp90ab1 and Hprt1) and presented as relative fold change. Pvalue was calculated using RT Profiler PCR Array Data Analysis Software (SABiosciences). (e) Detection of mouse Cdh11 protein by immunohistochemistry (rabbit polyclonal We also asked whether MUC1-targeted therapy can prolong survival and reverse immune dysregulation in MUC1KrasPten mice. To address this, we used a vaccine based on a synthetic 100mer MUC1 peptide (comprising five tandem repeats from the MUC1 extracellular domain), loaded onto dendritic cells (DC) matured under type 1 polarizing conditions (DC1). The DC1-MUC1 vaccine was administered subcutaneously (SC) in the right flank, at weeks 4, 6 and 8 after AdCre injection. A total of 3000 MUC1-loaded DC1 cells were administered in each vaccine. This low number represents the mouse mass-adjusted equivalent of an adult human vaccine of ~ 6.5 million DC. Our results show that the DC1-MUC1 vaccine significantly prolongs survival in vaccinated MUC1KrasPten mice (n = 10, P = 0.033) compared with MUC1KrasPten non-vaccinated mice (n = 13, Figure 5 ). No mice died before the scheduled time for the first vaccine dose. In follow up studies we used a novel transplantable ovarian cancer tumor model to test in vivo efficacy of a PD-L1 blockade. The therapeutic PD-L1 blockade employed three administrations of anti-PDL1 (200ug/dose/mouse) administered IP two weeks apart. Treatment was started 21 days after tumor induction, and administered intraperitoneal (IP) every two weeks for a total of 3 doses. Our results demonstrate that IP administration of anti-PD-L1 in a new preclinical model for aggressive ovarian cancer significantly increases survival ( Fig. 6 We profiled the miRNA and immune microenvironment in endometriosis and endometriosis-associated ovarian cancer (EAOC) using Nanostring and the nCounter® GX Human Immunology Kit, comprising probes for a total of 511 immune genes. Our studies revealed several miRNA signatures that can differentiate different disease categories (controls, benign precursors and cancer) (Fig. 7) Fig.7 . Plasma miRNA expression profiles can distinguish different disease categories. A) Unsupervised hierarchical clustering was applied to miRNAs with < 30% missing values in healthy controls, endometriosis, and EAOC samples (n=20, 33, and 14, respectively). Different distance measure and link were explored. Samples are classified into three clusters based on the expression signature of 23 plasma miRNAs. B) Principal component analysis was applied to markers with adjusted p value < 0.2 in either one of the three groups' pair-wised comparisons. One third of the endometriosis patients revealed a tumor-like inflammation profile, suggesting that cancer -like immune signatures may develop earlier, in patients classified as clinically benign (Fig. 8) . Gene expression analyses revealed the complement pathway as most prominently involved in both endometriosis and EAOC (Fig. 9) . These findings reveal new characteristics of inflammation in precursor lesions and point to previously unknown roles of complement in endometriosis and EAOC. Most importantly, our findings reveal that chronic inflammation in endometriosis is dominated by complement, which remains active in EAOC but not tumors with serous histology, further demonstrating heterogeneity in the inflammatory milieu within this category commonly referred to as ovarian cancer. Pharmacologic inhibition of complement is currently tested in clinical trials and results from these studies will provide much needed clinical evidence to support (or refute) the recent paradigm shift on pro-tumor roles of complement in cancer. Profiling studies like the one presented here might aid in patient selection for a personalized approach ( Timeline for milestones completed during the award period Milestone #1: first round of publication submissions. This milestone has been completed (1, 2). Milestone # 2: second round of publication submissions. This milestone has been completed (references 3,4 and 6) Milestone # 3: first R01 submission. Originally planned for year 3, we report that we secured our first R01 earlier than proposed, in year 2.
Milestone #4: promotion to tenured Associate Professor. Completed in year 5 of the award.
Opportunities for training and professional development
Due to this award the PI has been able to travel to one large professional meeting (like AACR or AAI) where she attended workshops and/or presented her work either as oral or platform presentations. Titles of presented work are listed below.
Result dissemination to communities of interest
The PI has presented her work to meetings attended by ovarian cancer survivors (TRC3, AACR Marsha Rivkin).
Goals for next reporting period
Nothing to report.
IMPACT
4.1. Impact on principal discipline Our studies have advanced our understanding of disease pathogenesis in ovarian cancer, particularly in endometriosis-associated ovarian cancer and our ability to design improved therapies via novel vaccines and immune biologics. 
Impact on other disciplines

Impact in technology transfer
We have developed new preclinical models (mice, cell lines) for ovarian cancer research. These models are currently (and will continue to be) shared via Material Transfer Agreements between the University of Pittsburgh and the institutions of requesting investigators.
Impact on society beyond science and technology
Our studies can lead to new clinical trials and improved treatments for ovarian cancer. Reducing suffering due to cancer can have a positive impact not only on cancer patients and their families but the society as a whole.
CHANGES/PROBLEMS
PRODUCTS
6.1 Publications, conference papers and presentations • Journal Publications (Peer Reviewed) 3. Suryawanshi S, Budiu R, Mantia G, Kim, SH, Tseng, G, Elishaev, E, Bhargava, R, Huang X, Edwards RP 
